Table 3. Estimation of the interaction between genotype and vaccine group for symptomatic VCD detected during the active phase of follow-up by serotype in all participants who received >= 1 injection (intention to treat) (CYD14/CYD15).

The estimate of the interaction term between genotype and vaccine group is derived from Cox proportional hazards regression models including the vaccine group, the genotype and the interaction.

		Estimated interaction with observed vaccine efficacy		Estimated interaction with vaccine efficacy with imputation
Serotype	Parameter	Parameter estimate	95%	Parameter estimate	95%
Serotype 1	Genotype IV vs Genotype I	−0.058	[−0.858; 0.743]	0.095	[−0.475; 0.665]
	Genotype V vs Genotype I	−0.167	[−0.936; 0.603]	0.067	[−0.492; 0.625]
Serotype 2	American/Asian vs Asian I	−0.732	[−1.486; 0.022]	−0.471	[−1.032; 0.089]
	Cosmopolitan vs Asian I	−0.404	[−1.259; 0.451]	−0.344	[−0.966; 0.267]
Serotype 3	Genotype II vs Genotype I	−12.748	[−729.203; 703.707]	−1.079	[−2.754; 0.596]
	Genotype III vs Genotype I	−0.251	[−1.208; 0.705]	−0.459	[−1.116; 0.198]
Serotype 4	Genotype II vs Genotype I	−1.114	[−1.943; −0.285]	−0.8184	[−1.434; −0.203]